Ashley has reported on health care market issues with Citleline and legacy companies since 1988, initially as a linguist on the France and Germany desk and later becoming editor of three titles. Two publications are his current focus for written and multimedia (panel moderating and podcasts) content: In Vivo (global medtech market access); and Medtech Insight (regulation and policy content for the UK, European and Asia markets).
Latest from Ashley Yeo
German medtech revenue growth has slowed, profit margins are being eroded, and exporters fear harsher US market access conditions on the return to office of President-Elect Donald Trump. The week became even more momentous with news of the collapse of the German government.
The milestones on MHRA’s in-progress medtech regulatory roadmap for Great Britain will be subject to some change in the coming months.
The Life Sciences Innovative Manufacturing Fund, set out in the UK budget last month, is live for applications. More UK medtechs would benefit if the cost threshold were scaled down, the industry argues.
UK chancellor of the exchequer Rachel Reeves said her 2024 budget announcement would address the problem of ‘hospitals being without the equipment they need.’
Findings of Germany’s latest annual survey of medtech opinion and business confidence are a wake-up call for European industry and heap further criticism on the EU MDR.
An agreement between the EU and Switzerland potentially opening the way for renewal of the MRA – enabling barrier-free cross-border medtech trade – could be concluded as early as December. More good news for Switzerland, relating to the acceptance of FDA-approved products into the country, could follow in Q1 2025.